Viewpoint Exportin(g) precision oncology beyond genomics with XPO1 inhibition

被引：0
|
作者：
Gouda, Mohamed A. [1 ]
Subbiah, Vivek [1 ,2 ,3 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Div Pediat, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, MD Anderson Canc Network, Houston, TX 77030 USA
来源：
MED | 2022年 / 3卷 / 11期
基金：
美国国家卫生研究院;
关键词：
D O I：
10.1016/j.medj.2022.10.005
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
We urgently need to identify new druggable targets for pediatric cancers. Coutinho et al.(1) identified and validated XPO1 aberrant activity in patients with Wilms tumor (WT) and malignant rhabdoid tumor (MRT) using public databases and report an early proof-of-concept bench-to-bedside translation of XPO1 inhibition in pediatric WT and MRT.
引用
收藏
页码：730 / 732
页数：3
相关论文
共 50 条
  • [1] Exportin 1 (XPO1) inhibition alone or in combination as a novel therapeutic strategy in osteosarcoma
    Graves, Laurie
    Rupprecht, Gabrielle
    Altunel, Erdem
    Flamant, Etienne M.
    Rao, Sneha
    Sivara, Dharshan
    Lazarides, Alexander L.
    Hoskinson, Sarah M.
    Sheth, Maya U.
    Cheng, Serene
    Kim, So Young
    Ware, Kathryn E.
    Agarwal, Anika
    Cullen, Mark M.
    Syal, Casey
    Selmic, Laura E.
    Everitt, Jeffrey I.
    McCall, Shannon J.
    Eward, Cindy
    Kashyap, Trinayan
    Maloof, Marie
    Walker, Christopher J.
    Landesman, Yosef
    Wagner, Lars
    Eward, William C.
    Hsu, David S.
    Somarelli, Jason A.
    CANCER RESEARCH, 2022, 82 (12)
  • [2] Effect of Exportin 1/XPO1 Nuclear Export Pathway Inhibition on Coronavirus Replication
    Rahman, Masmudur M.
    Estifanos, Bereket
    Glenn, Honor L.
    Gutierrez-Jensen, Ami D.
    Kibler, Karen
    Li, Yize
    Jacobs, Bertram
    Mcfadden, Grant
    Hogue, Brenda G.
    VIRUSES-BASEL, 2025, 17 (02):
  • [3] SELINEXOR Exportin-1(XPO1) inhibitor Oncolytic
    Riaz, W.
    Burke, N.
    Mahipal, A.
    DRUGS OF THE FUTURE, 2014, 39 (10) : 685 - 692
  • [4] AKTing on XPO1 inhibition in AML
    Stefanie Göllner
    Carsten Müller-Tidow
    Nature Cancer, 2022, 3 : 787 - 789
  • [5] Expression of exportin 1 (XPO1/CRM1) in pancreatic adenocarcinoma
    Saulino, David M.
    Younes, Pamela S.
    Biley, Jennifer M.
    Younes, Mamoun
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [6] AKTing on XPO1 inhibition in AML
    Goellner, Stefanie
    Mueller-Tidow, Carsten
    NATURE CANCER, 2022, 3 (07) : 787 - 789
  • [7] Exportin-1 (XPO1) is a novel therapeutic biomarker for patients with neuroblastoma
    Galinski, Basia
    Luxemburg, Marcus
    Ewart, Michelle
    Landesman, Yosef
    Weiser, Daniel
    CANCER RESEARCH, 2017, 77
  • [8] Inhibition of exportin 1 (XPO1) by selinexor (KPT-330) synergistically suppresses growth of neuroblastoma in combination with doxorubicin or bromodomain inhibition
    Ranieri, Pietro J.
    Trillo, Rebecca
    Landesman, Yosef
    Senapedis, William
    McCauley, Dilara
    Shacham, Sharon
    Kauffman, Michael
    Maris, John M.
    Attiyeh, Edward F.
    CANCER RESEARCH, 2015, 75
  • [9] XPO1/Exportin-1 in Acute Myelogenous Leukemia; Biology and Therapeutic Targeting
    Bruserud, Oystein
    Selheim, Frode
    Hernandez-Valladares, Maria
    Reikvam, Hakon
    BIOMOLECULES, 2025, 15 (02)
  • [10] Exportin-1 (XPO1, CRM1) inhibitors for the management of viral infection
    Heaton, S. M.
    DRUGS OF THE FUTURE, 2021, 46 (03) : 207 - 215
12345